Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Unfallchirurg ; 105(9): 845-50, 2002 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-12232745

RESUMO

Thrombosis prophylaxis using heparins is mandatory in most trauma patients. However, heparins can induce heparin-induced thrombocytopenia (HIT), the most common and clinically important immune-mediated drug-dependent thrombocytopenia. Affected patients are at risk of developing new thromboembolic complications. HIT has to be considered if platelet counts decrease >50% between day 5-10 of heparin therapy that cannot be explained alternatively or if new thromboses occur in a sufficiently heparinised patient. Immediately changing the anticoagulant to danaparoid or lepirudin is most important. Proof of anti-platelet-factor-4/heparin antibodies secures the diagnosis, usually retrospectively. Diagnosis and therapy are demonstrated in a typical HIT patient. HIT usually occurs in the second week of heparin administration. Heparin-reexposure within 100 days can lead to HIT before day 5. For early recognition of HIT, platelet counts should be monitored regularly. Because of earlier discharge of patients to rehabilitation or outpatient care, the problem of HIT-diagnosis and therapy gains increasing relevance in these sectors.


Assuntos
Fraturas Ósseas/cirurgia , Heparina/efeitos adversos , Hirudinas/análogos & derivados , Traumatismo Múltiplo/cirurgia , Complicações Pós-Operatórias/prevenção & controle , Trombocitopenia/induzido quimicamente , Tromboembolia/prevenção & controle , Adulto , Anticoagulantes/administração & dosagem , Autoanticorpos/sangue , Sulfatos de Condroitina/administração & dosagem , Dermatan Sulfato/administração & dosagem , Combinação de Medicamentos , Heparina/administração & dosagem , Heparitina Sulfato/administração & dosagem , Hirudinas/administração & dosagem , Humanos , Masculino , Contagem de Plaquetas , Fator Plaquetário 4/imunologia , Proteínas Recombinantes/administração & dosagem , Trombocitopenia/diagnóstico , Trombocitopenia/tratamento farmacológico , Tromboembolia/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA